[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352487-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352487-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","semi-quantitative-evaluation-of-brca1-protein-in-breast-tumors-using-anti-brca1-antibodies-clinical-implications","Semi-Quantitative Evaluation of BRCA1 Protein in Breast Tumors Using Anti-BRCA1 Antibodies - Clinical Implications","","Aggressive breast cancer subtypes, including triple-negative breast cancer (TNBC) and tumors arising in BRCA1 germline mutation carriers, create major clinical challenges. BRCA1 protein expression, evaluated through immunohistochemistry (IHC), has not been fully defined as a driver of high-risk tumor biology. A semi-quantitative IHC study quantified BRCA1 in a targeted cohort of 100 invasive carcinomas enriched for TNBC and BRCA1 mutations. Low BRCA1 expression correlated with aggressive histology, receptor negativity, TNBC subtype, necrosis, denser mononuclear infiltrates, and an inverse relationship with p16 overexpression. The study supports BRCA1 IHC as a complementary biomarker while emphasizing it cannot replace germline testing for targeted-therapy decisions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/semi-quantitative-evaluation-of-brca1-protein-in-breast-tumors-using-anti-brca1-antibodies-clinical-implications/352487/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/semi-quantitative-evaluation-of-brca1-protein-in-breast-tumors-using-anti-brca1-antibodies-clinical-implications/352487.png","ImageObject",300,407,{"name":42,"@type":43},"Rowan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was evaluated in this study and how was BRCA1 expression measured?","Question",{"text":63,"@type":64},"BRCA1 protein expression was assessed using semi-quantitative immunohistochemistry (IHC) with a validated monoclonal antibody and a composite scoring system.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which clinicopathological features were associated with low BRCA1 expression?",{"text":68,"@type":64},"Low BRCA1 expression showed strong associations with aggressive phenotype indicators, including invasive ductal histology, hormone receptor negativity, and the TNBC subtype.",{"name":70,"@type":61,"acceptedAnswer":71},"How do the findings position BRCA1 IHC in clinical decision-making?",{"text":72,"@type":64},"BRCA1 IHC is presented as a complementary biomarker for characterizing high-risk tumor biology, while germline genetic testing remains necessary for targeted-therapy decisions.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352487,1790874164,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Article  \nSemi-Quantitative Evaluation of BRCA1 Protein in Breast Tumors Using Anti-BRCA1 Antibodies: Clinical Implications  \nSorana Caterina Anton 1,†, Alin Horatiu Nedelcu 1, Victor Ianole 1,2, *, Carmen Anton 1,3,†, Mihai Danciu 1,3, Ionela Daniela Morariu 4, Ancua Lupu 1, Gabriel Dascalescu 5,6, Vasile Valeriu Lupu 1, Anton Knieling 1, Delia Nicolaiciuc 1, Alin Ciobica 5,6,7,8, Elena Andreea Chivasuta 1,2, Mihaela Tirnovanu 1, Iurie Dondiuc 9, Ciprian Ilea 1, Mihaela Grigore 1 and Emil Anton 1  \nAcademic Editor: Ioannis Boutas  \nReceived: 16 January 2026  \nRevised: 6 February 2026  \nAccepted: 9 February 2026  \nPublished: 11 February 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Faculty of Medicine,“Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania; alin.nedelcu@umfiasi.ro (A.H.N.); mihai.danciu@umfiasi.ro (M.D.); ancuta.ignat1@umfiasi.ro (A.L.); vasile.lupu@umfiasi.ro (V.V.L.); emil.anton@umfiasi.ro (E.A.)  \n2 Department of Pathology,“Prof. Dr. Nicolae Oblu” Emergency Clinical Hospital, 700309 Iasi, Romania  \n3 Department of Pathology,“Saint Spiridon” County Hospital, 700111 Iasi, Romania  \n4 Faculty of Pharmacy,“Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania  \n5 Department of Biology, Faculty of Biology, Alexandru Ioan Cuza University of Iasi, B-Dul Carol I, No. 11, 700506 Iasi, Romania; [gabidascalescu2001@gmail.com](gabidascalescu2001@gmail.com) (G.D.)  \n6 “Ioan Haulica” Institute, Apollonia University, 700511 Iasi, Romania  \n7 CENEMED Platform for Interdisciplinary Research,“Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania  \n8 Biomedical Research Group,“Olga Necrasov” Center, Romanian Academy, Iasi Branch, Teodor Codrescu 2, 700481 Iasi, Romania  \n9 Department of Obstetrics and Gynecology,“Nicolae Testemitanu” University of Medicine and Pharmacy, 2004 Chisinau, Moldova  \n* [Correspondence: ianole.victor@umfiasi.ro](Correspondence: ianole.victor@umfiasi.ro)[ ](Correspondence: ianole.victor@umfiasi.ro)† These authors contributed equally to this work.  \nAbstract  \nAggressive breast cancer subtypes, such as triple-negative breast cancer (TNBC) and tumors in BRCA1 germline mutation carriers, present significant clinical challenges. The role of BRCA1 protein expression, assessed via immunohistochemistry (IHC), in defining the biology of these high-risk tumors remains to be fully elucidated. We performed a semi-quantitative IHC analysis of BRCA1 protein expression in a targeted cohort of 100 invasive breast carcinomas, enriched for TNBC (88%) and BRCA1 mutation carriers (34%) . A validated monoclonal antibody and a composite scoring system (0–9) were employed, with an optimal cut-off defined by ROC analysis. Associations with clinicopathological parameters and p16 expression were evaluated. Low BRCA1 expression was strongly associated with an aggressive phenotype, including invasive ductal histology, hormone receptor negativity, and the TNBC subtype (all p \u003C 0.001) . Tumors with BRCA1 loss exhibited a more pro-tumorigenic microenvironment, characterized by higher rates of necrosis (p = 0.014) and denser mononuclear infiltrates (p = 0.019) . A significant inverse correlation with p16 overexpression was identified (p = 0.030) . Our findings demonstrate that BRCA1 protein loss delineates a distinct aggressive tumor biology within high-risk breast cancers. We emphasize that BRCA1 IHC is a complementary biomarker and cannot supplant germline genetic testing for clinical decision-making regarding targeted therapies.  \nKeywords: BRCA1; immunohistochemistry; triple-negative breast cancer; tumor microenvironment; biomarker  \n1. Introduction  \nBreast cancer remains a major global health challenge, characterized by significant molecular and clinical heterogeneity [1] . Among its subtypes, trip","cbCailDauRTMsmXb","https://ap.wps.com/l/cbCailDauRTMsmXb","pdf",977603,13,"English","# Abstract\n# Introduction\n## Clinical challenge and study rationale\n## Role of BRCA1 in genome maintenance\n## BRCA1-related and BRCA-like tumor phenotypes\n## Controversies in BRCA1 localization and prognosis\n## Rationale for immunohistochemistry (IHC)","[{\"question\":\"What was evaluated in this study and how was BRCA1 expression measured?\",\"answer\":\"BRCA1 protein expression was assessed using semi-quantitative immunohistochemistry (IHC) with a validated monoclonal antibody and a composite scoring system.\"},{\"question\":\"Which clinicopathological features were associated with low BRCA1 expression?\",\"answer\":\"Low BRCA1 expression showed strong associations with aggressive phenotype indicators, including invasive ductal histology, hormone receptor negativity, and the TNBC subtype.\"},{\"question\":\"How do the findings position BRCA1 IHC in clinical decision-making?\",\"answer\":\"BRCA1 IHC is presented as a complementary biomarker for characterizing high-risk tumor biology, while germline genetic testing remains necessary for targeted-therapy decisions.\"}]","Semi-Quantitative Evaluation of BRCA1 Protein in Breast Tumors Using Anti-BRCA1 Antibodies - Clinical Implications | PDF",1790099881,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/34021a5b17dfe61fefc732a5bd258953.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce2646777c374f533896c4b090b82cfc.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b51c12ba440ebbde026756e6ed1e4756.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f6e75f19b9fb83020b6417fd9d9aed5.webp",980,1385]